Panel Discussion: Working Around Clinical Trial Challenges for Retinal Vascular Disease Drug Development

Time: 5:15 pm
day: Day One


• Discussing challenges of getting the next generation of therapeutics approved for DME and nAMD

• Highlighting the novel end points beyond BCVA to establish meaningful differentiation from VEGF therapy

• Overcoming challenges with regulators and payers to get approval and funding for therapies